Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’
Titel:
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’
Auteur:
Burotto, M. Zvirbule, Z. Mochalova, A. Runglodvatana, Y. Herraez-Baranda, L. Liu, S.N. Chan, P. Shearer-Kang, E. Liu, X. Tosti, N. Zanghi, J.A. Leutgeb, B. Felip, E.